P078 | A SIGNIFICANT DOSE REDUCTION OF VENETOCLAX DOES NOT AFFECT RESPONSE RATE AND OVERALL SURVIVAL OF AML PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
Background. The VIALE-A study showed that the combination of Azacitidine and Venetoclax (AzaVen) is effective in patients (pts) with Acute Myeloid Leukemia (AML) not eligible for intensive treatment. However, it is common experience that the original scheme of VIALE-A study is difficult to apply in...
| Published in: | Haematologica |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-09-01
|
| Online Access: | https://haematologica.org/article/view/12475 |